PATENT CLAIM ANALYSIS

Application Number: 16301826
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "254060"]

Abstract:
The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.

Claim (Index 22):
The crystalline Form 4 according to  claims 19 ,  20  or  21 , wherein said crystalline form is further characterized by exhibiting a peak in a differential scanning calorimetry scan of from about 200\u00b0 C. to about 205\u00b0 C.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 98.0
- Lexical Diversity: 1.13636
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14623904', '16050516', '16051815', '14953969', '15172478']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7727498948727218
- 35 USC 102 Novelty (BERT): 0.524877280554103
- Combined Prediction Score: 0.74796263344086
- Mean Citation Score: 293.132042
- Max Citation Score: 305.8803
- Similarity Product: 180.00210395565034

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test